125 related articles for article (PubMed ID: 2684001)
1. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
[TBL] [Abstract][Full Text] [Related]
2. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases.
Lin M; Hanai J; Wada A; Ozaki M; Nasu K; Okamoto S; Matsumoto K
Acta Pathol Jpn; 1991 Mar; 41(3):233-9. PubMed ID: 2068948
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical characterization of ovarian borderline tumors of intestinal and mullerian types.
Rutgers JL; Bell DA
Mod Pathol; 1992 Jul; 5(4):367-71. PubMed ID: 1495942
[TBL] [Abstract][Full Text] [Related]
4. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical demonstration of CA 125, CA 19-9 and CEA in normal and pathologically changed adnexa].
Neunteufel W; Breitenecker G
Geburtshilfe Frauenheilkd; 1988 May; 48(5):334-7. PubMed ID: 3165079
[TBL] [Abstract][Full Text] [Related]
6. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
Oishi T; Maruo T; Iwasaki M; Mochizuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
[TBL] [Abstract][Full Text] [Related]
9. Blood group substance, CEA, and lectins in ovarian tumors.
Dietel M; Arps H; Hölzel F; Viale G; Dell'Orto P; Kröger A; Niendorf A
Cancer Detect Prev; 1986; 9(5-6):511-20. PubMed ID: 3465441
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
11. [Carcinoma with low malignant potential (borderline tumor) of the ovary: immunomorphology and clinical aspects].
Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
Arch Gynecol Obstet; 1989; 245(1-4):600-2. PubMed ID: 2679431
[TBL] [Abstract][Full Text] [Related]
12. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
Neunteufel W; Breitenecker G
Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
14. The value of epithelial membrane antigen in the diagnosis of ovarian tumors.
Fujimoto I; Hirai Y; Hasumi K; Masubuchi K; Osamura Y
Acta Cytol; 1990; 34(4):549-54. PubMed ID: 1695804
[TBL] [Abstract][Full Text] [Related]
15. Mucinous tumors of the ovary: a review.
Hart WR
Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
[TBL] [Abstract][Full Text] [Related]
16. Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies.
van Niekerk CC; Vooijs P; Casparie-van Velsen IJ; Poels LG
Cancer Detect Prev; 1997; 21(3):247-57. PubMed ID: 9167042
[TBL] [Abstract][Full Text] [Related]
17. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen (CEA) and gastrointestinal cancer associated antigen CA 19-9 in bronchioloalveolar carcinomas and pulmonary adenocarcinomas.
Heikkilä L; Suomalainen RJ; Lindgren J; Jalanko H; Harjula A; Mattila S
Ann Chir Gynaecol; 1986; 75(5):260-5. PubMed ID: 3030184
[TBL] [Abstract][Full Text] [Related]
19. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
20. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
